Investors have no reason to panic over Apple's decision to substitute Phil Schiller for Steve Jobs at Macworld 2009, and abandon the expo entirely in 2010, say analysts with Needham & Co. and Kaufman Bros.. The former notes that the substitution is bound to raise questions over Jobs' health, given a gaunt appearance in recent months, and largely discredited rumors of cancer recurrence. Needham c
